3645 results for «569»
3645 results
DCB - Going beyond in-stent restenosis
20 May 2026 – From EuroPCR 2026
This session examines the expanding role of drug-coated balloons (DCB) beyond in-stent restenosis, including treatment of acute coronary syndromes, calcified lesions, and bifurcations. It reviews current evidence supporting DCB-based revascularization and outlines essential procedural steps to optimize outcomes.
Prognostics elements on multivessel disease and coronary artery disease
20 May 2026 – From EuroPCR 2026
This session examines key prognostic elements in multivessel and coronary artery disease, featuring studies on mechanical circulatory support across LDL-C levels, biomarkers impacting periprocedural myocardial infarction, autologous cell therapy outcomes for refractory angina, and novel risk stratification indices. It also addresses prognosis in cancer patients and...
Reliability and application of angio-based physiology in daily work
20 May 2026 – From EuroPCR 2026
This session evaluates the reliability and clinical application of angiography-based physiological assessments in daily practice. Topics include comparisons of angiography-derived microvascular resistance and flow metrics with invasive methods, reproducibility of quantitative flow ratio (QFR), and its correlation with symptom burden and other imaging modalities.
Lost, crushed, fractured: stent complications in real life
20 May 2026 – From EuroPCR 2026
This session addresses real-world challenges of stent complications including loss, crushing, and fracture during PCI. Through case-based discussions, it explores complex scenarios such as stent dislodgement, embolisation, and management strategies when initial plans evolve into complicated realities.
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
